MannKind Corporation today announced that it has submitted a New Drug Application (NDA) to the U.S. FDA requesting approval of AFRESA(R) (insulin monomer human [rDNA origin]) Inhalation Powder and the AFRESA(R) Inhaler for the treatment of adults with type 1 or type 2 diabetes mellitus for the control of hyperglycemia.
the details can be read here.
No comments:
Post a Comment